title: 90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma.
abstract: Targeted radioimmunotherapy with (90)Y-labeled ibritumomab tiuxetan is a novel therapeutic approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  Seven consecutive patients with CD20-positive aggressive NHL who did not fully respond to prior myeloablative chemotherapy were enrolled. A 14.8 MBq (0.4 mCi)/kg dose of (90)Y-ibritumomab tiuxetan was administered to all patients, and approximately 100 d afterward (18)F-FDG PET/CT was performed to assess response.
  
  
  RESULTS
  PET/CT showed a complete response in 5 of 7 patients. Of the 2 nonresponsive patients, 1 showed persistent disease and the other progression. Toxicity included thrombocytopenia in all 7 patients and grade IV neutropenic fever in 1 patient.
  
  
  CONCLUSIONS
  Despite the small series studied, we suggest that radioimmunotherapy is safe for consolidation in patients treated with high-dose chemotherapy for aggressive NHL and may provide clinical benefit in extensively pretreated patients.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy. ria@dimo.uniba.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Ria
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Antonia
authors.initials: A
authors.lastname: Reale
authors.forename: Roberto
authors.initials: R
authors.lastname: Guariglia
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Iodice
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C422802:ibritumomab tiuxetan